ArticleMedical oncology (Northwood, London, England)2011
Altered expression of selenium-binding protein 1 in gastric carcinoma and precursor lesions.
Article in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- The role of SELENBP1 and its epigenetic regulation in carcinogenic progression.Frontiers in genetics · 2022Review
- Selenium-Binding Protein 1 in Human Health and Disease.International journal of molecular sciences · 2018Review
- Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4.American journal of cancer research · 2018Article
- Selenium-binding protein 1 in head and neck cancer is low-expression and associates with the prognosis of nasopharyngeal carcinoma.Medicine · 2016Article
- Review
- Does aberrant membrane transport contribute to poor outcome in adult acute myeloid leukemia?Frontiers in pharmacology · 2015Article
- Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma.World journal of surgical oncology · 2014Article
- Human selenium binding protein-1 (hSP56) is a negative regulator of HIF-1α and suppresses the malignant characteristics of prostate cancer cells.BMB reports · 2014Article
- Molecular cross-talk between members of distinct families of selenium containing proteins.Molecular nutrition & food research · 2014Review
- Dysregulation of microRNA biosynthesis enzyme Dicer plays an important role in gastric cancer progression.International journal of clinical and experimental pathology · 2014Article
- Selenium-binding protein 1 as a tumor suppressor and a prognostic indicator of clinical outcome.Biomarker research · 2013Article
- Up-regulation of Ago2 expression in gastric carcinoma.Medical oncology (Northwood, London, England) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selenium-binding protein 1 (SBP1) has been shown to be greatly reduced in various human cancers. The purpose of this study was to evaluate the expression of SBP1 in precursor lesions and gastric carcinoma (GC) and to discuss the specific role of SBP1 in gastric carcinogenesis. Using tissue microarray (TMA) technology and immunohistochemical (IHC) survey, SBP1 expressions were evaluated based on a semi-quantitative scoring system developed for this study in 25 paired of GC and corresponding nonneoplastic epithelia tissues, 21 gastric ulcer, 13 gastric polyp, 19 chronic atrophic gastritis, 20 intestinal metaplasia, and 16 dysplasia tissues. We found abundant expression of SBP1 in most precursor lesions in addition to the nonneoplastic epithelia tissues. However, the expression of SBP1 was severely suppressed in most of the GC tissues (P=0.000). Although no statistical differences were found between the expressions of SBP1 in gastric tissues with different levels of intestinal metaplasia or dysplasia (P>0.05), the reduction in SBP1 seems to be correlated with clinical stage of GC (P=0.044). Thus, SBP1 can be supposed as a diagnosis marker of GC. The suppression of SBP1 may be a late event in gastric carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.